Sort   by:  
 Page size 
ProteomicsCharacterization of PARP-6 function in knock out mice and patients with developmental delay
PARP-6, a member of a family of enzymes (17 in humans) known as poly-ADP- ribose polymerases (PARPs), is a neuronally enriched PARP. While previous studies from our group show that PARP-6 is a regulator of dendrite morphogenesis in hippocampal neurons, its function in the nervous system in vivo is p...
ORGANISM(S): Mus musculus (Mouse) 
2021-07-21 | PXD025386 | Pride
Dendritic branching Parp-6  nervous system Marylation Bioid Spectral counts Adp-ribosylation Orbitrap fusion 
GenomicsInnate and Acquired Transcriptional Programs Shape Heterogeneous Tumor Cell Responses to PARP, Akt, and CDK4/6 Inhibitors
Innate and Acquired Transcriptional Programs Shape Heterogeneous Tumor Cell Responses to PARP, Akt, and CDK4/6 Inhibitors
PRJNA1456597 | ENA
Unknown6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
Not available
S-EPMC2913123 | biostudies-literature
UnknownInhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Not available
S-EPMC6236629 | biostudies-literature
GenomicsEssential role of poly(ADP-ribosyl)ation in cocaine action
Many of the long-term effects of cocaine on the brain's reward circuitry have been shown to be mediated by alterations in gene expression. Several chromatin modifications, including histone acetylation and methylation, have been implicated in this regulation, but the effect of other histone modifica...
ORGANISM(S): Mus musculus 
2014-02-20 | E-GEOD-55136 | biostudies-arrayexpress
UnknownCDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer.
Not available
S-EPMC11683282 | biostudies-literature
UnknownEfficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines.
Not available
S-EPMC10394730 | biostudies-literature
UnknownA Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
Not available
S-EPMC8911181 | biostudies-literature
UnknownAdenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling.
Not available
S-EPMC10399543 | biostudies-literature
TranscriptomicsInnate and Acquired Transcriptional Programs Shape Heterogeneous Tumor Cell Responses to PARP, Akt, and CDK4/6 Inhibitors
Targeted therapies are increasingly utilized across cancer types, yet their efficacy in triple-negative breast cancer (TNBC) remains limited due to the disease’s high heterogeneity and aggressive nature. In a heterogeneous tumor, treatment failure can occur due to the presence of therapy-tolerant ce...
ORGANISM(S): Homo sapiens 
2026-05-01 | GSE328823 | GEO
Sort   by:  
 Page size